NHS Framework Agreement, Branded Medicines for London and South of England

A Contract Award Notice
by NHS ENGLAND

Source
Contracts Finder
Type
Framework (Products)
Duration
2 year
Value
£442M
Sector
HEALTH
Published
17 Sep 2021
Delivery
01 Sep 2021 to 31 Aug 2023
Deadline
04 Jun 2021 13:00

Concepts

Location

Geochart for 1 buyers and 42 suppliers

1 buyer

42 suppliers

Description

NHS Framework Agreement, Branded Medicines for London and South of England Offer reference number: CM/PHR/20/5598 FIND A TENDER (FTS) Reference number: FTS-002229 CM/PHR/20/5598/01 - NHS Framework for LONDON Branded Medicines - Tranche B. Period of framework: 1 September 2021 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/20/5598/02 - NHS Framework for the LONDON Branded Medicines - Annual Tranche. Period of framework: 1 September 2021 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months CM/PHR/20/5598/03 - NHS Framework for the SOUTH of England Tranche A. Period of Framework: 1 September 2021 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/20/5598/04- NHS Framework for SOUTH of England - Tranche B. Period of framework: 1 September 2021 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months CM/PHR/20/5598/05 - NHS Framework for the SOUTH of England Annual Tranche. Period of Framework: 1 September 2021 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months CM/PHR/20/5598/06 - NHS Framework for the Midlands & East and North of England Regions - Bevacizumab Period of Framework: 1 September 2021 to 28 February 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 6 months

Award Detail

1 Drreddys Laboratories (Beverley)
  • Value: £558,521,926
2 Accord (None)
  • Value: £558,521,926
3 Techdow Pharma England (Guildford)
  • Value: £558,521,926
4 Ul Global Pharma (None)
  • Value: £558,521,926
5 Biogen (Maidenhead)
  • Value: £558,521,926
6 Amgen (Cambridge)
  • Value: £558,521,926
7 Thornton & Ross (Huddersfield)
  • Value: £558,521,926
8 Merck Sharpe & Dohme (London)
  • Value: £558,521,926
9 Bayer (Reading)
  • Value: £558,521,926
10 Zentiva Pharma (London)
  • Value: £558,521,926
11 Napp Pharmaceuticals (Cambridge)
  • Value: £558,521,926
12 Novo Nordisk (Gatwick)
  • Value: £558,521,926
13 Daiichi Sankyo (Uxbridge)
  • Value: £558,521,926
14 Gedeon Richter (Maida Vale)
  • Value: £558,521,926
15 Teva (Castleford)
  • Value: £558,521,926
16 Pfizer (None)
  • Value: £558,521,926
17 Roche Products (Garden City)
  • Value: £558,521,926
18 Janssen Cilag (High Wycombe)
  • Value: £558,521,926
19 Mylan (Barnet)
  • Value: £558,521,926
20 Allergan (Marlow)
  • Value: £558,521,926
21 Organon Pharmaceuticals (London)
  • Value: £558,521,926
22 Sandoz (Camberley)
  • Value: £558,521,926
23 Celltrion Healthcare (Slough)
  • Value: £558,521,926
24 Sobi Swedish Orphan Biovitrum (None)
  • Value: £558,521,926
25 Merck Serono (Feltham)
  • Value: £558,521,926
26 Bristol Myers Squibb (Uxbridge)
  • Value: £558,521,926
27 Eli Lilly (Basingstoke)
  • Value: £558,521,926
28 Vifor Pharma (London)
  • Value: £558,521,926
29 Merz (Hemel Hempstead)
  • Value: £558,521,926
30 Takeda (London)
  • Value: £558,521,926
31 Astrazeneca (Luton)
  • Value: £558,521,926
32 Ferring Pharmaceuticals (West Drayton)
  • Value: £558,521,926
33 Aventis Pharma (Reading)
  • Value: £558,521,926
34 Pharmacosmos (Reading)
  • Value: £558,521,926
35 Tetris Pharma (Northampton)
  • Value: £558,521,926
36 Ipsen (Slough)
  • Value: £558,521,926
37 Profile Pharma (Chichester)
  • Value: £558,521,926
38 CST Pharma (Walsall)
  • Value: £558,521,926
39 Gilead Sciences (Holborn)
  • Value: £558,521,926
40 Morningside Pharmaeuticals (Northampton)
  • Value: £558,521,926
41 Chugai (Chiswick)
  • Value: £558,521,926
42 Ucb (Slough)
  • Value: £558,521,926

CPV Codes

  • 33600000 - Pharmaceutical products

Indicators

  • Contract is suitable for SMEs.

Reference

Domains